¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"multiple system atrophy"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
¿µ¹® system ÇÑ±Û °è, °èÅë
¼³¸í   
  ÀÎü¸¦ ±¸¼ºÇϴ °è´Â ´ÙÀ½°ú °°ÀÌ ±¸ºÐµÈ´Ù.
  
  1) ½ÉÀåÇ÷°ü°èÅë(cardiovascular system)
  
  2) È£Èí±â°è(respiratory system)
  
  3) ¼ÒÈ­±â°è(digeshive system)
  
  4) ºñ´¢±â°è(urinary system)
  
  5) »ý½Ä±â°è(genital system)
  
  6) Ç÷¾×°è(hematologic system)
  
  7) ³»ºÐºñ°è(endocrine system)
  
  8) ½Å°æ°è(nervous system)
  
  9) °ñ°Ý°è(skeletal system)
  
  10) ±ÙÀ°°è(muscular system)
  
  11) ÇǺΰè(integumentary system).
¿µ¹® sympathetic nervous system ÇÑ±Û ±³°¨½Å°æ°è
¼³¸í   
  ÀÚÀ²½Å°æ°èÀÇ ÀÏÁ¾À¸·Î ³»Àå±â´ÉÀ» ÁַΠÇ×Áø½ÃÄѠȰµ¿À» Áõ°¡½Ã۴ ±â´ÉÀ» °¡Áø´Ù. ÀÚÀ²½Å°æ°èÀÇ ´Ù¸¥ °è¿­ÀΠºÎ±³°¨½Å°æ°è´Â ¹Ý´ë·Î ³»Àå±â´ÉÀ» ¾ïÁ¦½ÃÄÑ ¿¡³ÊÁö¸¦ ºñÃàÇϴ ±â´ÉÀ» °¡Áø´Ù. ÀÚÀ²½Å°æ°èÀÇ ÇØºÎÇÐÀû Æ¯¼ºÀº ½Å°æÀÌ ÁßÃ߽Űæ°è¿¡¼­ ³ª¿Í ¸ñÇ¥Àå±â¿¡ µµ´ÞÇϱâ Àü¿¡ ÇѹøÀÇ ½Ã³À½º(synapse)¸¦ ÀÌ·é´Ù´Â Á¡À̸ç, µû¶ó¼­ ÀÚÀ²½Å°æ°è´Â µÎ °³ÀÇ ½Å°æ(½Ã³À½º¸¦ ÀÌ·ç±â ÀüÀÇ ÀýÀü½Å°æ°ú ÀÌ·é ÈÄÀÇ ÀýÈĽŰæ)À¸·Î ±¸¼ºµÈ´Ù. ÀÚÀ²½Å°æ°èÁß ±³°¨½Å°æ°è´Â ÁßÃ߽Űæ°è Áï Ã´¼ö ºÎ±ÙÀÇ ±³°¨½Å°æÀý(sympathetic ganglion)¿¡¼­ ½Ã³À½º°¡ ÀϾ°í, ºÎ±³°¨ ½Å°æ°è´Â ÁßÃ߽Űæ°è¿¡¼­ ¸Ö¸® ¶³¾îÁø ¸ñÇ¥ Àå±âºÎ±ÙÀÇ ½Å°æÀý(ganglion)¿¡¼­ ½Ã³À½º°¡ ÀϾ´Â Á¡ÀÌ ´Ù¸£´Ù.
¿µ¹® musculoskeletal System ÇÑ±Û ±Ù°ñ°Ý°è
¼³¸í   
  ±ÙÀ°°ú À̵頱ÙÀ°ÀÌ ºÙ¾î¼­ °°À̠Ȱµ¿À» ¼öÇàÇϴ °ñ°Ý(»À¸¦ ÅëÅо»ÇÔ)À» ÇÔ²² ºÎ¸£´Â ¸». µû¶ó¼­ ¿©±âÀÇ ±ÙÀ°Àº ¸ðµÎ °¡·Î¹«´Ì±Ù¿¡ ¼ÓÇϸç, ¼öÀÇÀûÀ¸·Î ¿òÁ÷ÀÏ ¼ö ÀÖ´Ù.
¿µ¹® muscular system ÇÑ±Û ±ÙÀ°°èÅë
¼³¸í   
  ±ÙÀ°¿¡ ÀÇÇØ ÀÌ·ç¾îÁø ÇϳªÀÇ °èÅëÀ» ÀÓÀÇÀûÀ¸·Î ³ª´©¾î ºÎ¸¥ ¸».
¿µ¹® male reproductive system ÇÑ±Û ³²¼º»ý½Ä±â°è
¼³¸í   
  ³²¼ºÀÇ »ý½Ä±â´Â ¿©·¯ ±â°üÀ¸·Î ±¸¼ºµÇ¾î ÀÖ´Ù. °íȯ, ºÎ°íȯ, Á¤°ü, Á¤³¶, Àü¸³»ù, ¿ÜºÎ¼º±â(À½°æ) µîÀ¸·Î ±¸¼ºµÇ´Âµ¥, ½ÇÁ¦ÀûÀ¸·Î Á¤ÀÚ¸¦ »ý¼ºÇϴ °÷Àº ´Ü ÇÑ °÷ °íȯ»ÓÀ̸ç, ³ª¸ÓÁö ±â°üÀº À̸¦ µ½´Â ±â´ÉÀ» ¼öÇàÇϰí ÀÖ´Ù. Á¤Àڴ °íȯÀÇ Á¤¼¼°üÀ̶õ °÷¿¡¼­ ¸¸µé¾îÁø µÚ¿¡ ¹ÛÀ¸·Î ³ª¿Í ±ä ¿©Á¤À» ½ÃÀÛÇϰԠµÈ´Ù. ±× µÚ ºÎ°íȯÀ» Áö³ª Á» ´õ ¼º¼÷ÇØ Áø µÚ¿¡ Á¤°ü¿¡¼­ Á¤³¶ÀÇ ºÐºñ¹°°ú ¸¸³ª°í ´Ù½Ã ¿äµµ·Î ³ª°¡°Ô µÈ´Ù. À̶§ ¿äµµ µÚÂÊ¿¡ À§Ä¡Çϴ Àü¸³»ùÀÇ ºÐºñ¹°ÀÌ ÇÕÃÄÁö°Ô µÇ°í ÀÌ Á¤¾×Àº ¿ÜºÎ¼º±â¸¦ °ÅÃļ­ ¹ÛÀ¸·Î ³ª°¡°Ô µÈ´Ù.
  
  ³²¼º»ý½Ä±â°è
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • lactation atrophy
    ¼öÀ¯¼ºÀÚ±ÃÀ§Ãà
  • muscular atrophy
    ±Ù(À°)À§Ãà
  • myopathic atrophy
    ±Ù(À°)º´¼ºÀ§Ãà
  • macular atrophy
    1. ÇǺιÝÁ¡À§Ãà(Áõ) 2. Ȳ¹ÝÀ§Ãà
  • neurogenic muscular atrophy
    ½Å°æ¼º±Ù(À°)À§Ãà
  • olivopontocerebellar atrophy
    ¿Ã¸®ºê´Ù¸®³ú¼Ò³úÀ§Ãà
  • optic atrophy
    ½Ã(°¢)½Å°æÀ§Ãà
  • optic nerve atrophy
    ½Ã(°¢)½Å°æÀ§Ãà
  • pigmentary atrophy
    »ö¼Ò¼ºÀ§Ãà
  • pressure atrophy
    ¾Ð¹ÚÀ§Ãà
  • progressive spinal muscular atrophy
    ÁøÇàô¼ö¼º±Ù(À°)À§ÃàÁõ
  • perifollicular macular atrophy
    ÅÐÁýÁÖÀ§¹ÝÁ¡À§Ãà
  • peripapillary chorioretinal atrophy
    À¯µÎÁÖÀ§¸Æ¶ô¸Á¸·À§Ãà
  • reticular atrophy
    ±×¹°À§Ãà, ¸Á»óÀ§Ãà
  • spinal muscular atrophy
    ô¼ö±Ù(À°)À§ÃàÁõ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • Bethesta system
    º£Å×½ºÅ¸ºÐ·ù(¹ý)
  • biliary system
    ´ãµµ°è, ¾µ°³°èÅë
  • blood group system
    Ç÷¾×Çü±º
  • central nervous system
    ÁßÃ߽Űæ°è, ÁßÃ߽Űæ°èÅë
  • information system
    Á¤º¸Ã¼°è
  • lymphatic system
    ¸²ÇÁ°èÅë
  • nervous system
    ½Å°æ°è, ½Å°æ°èÅë
  • open system
    1. °³¹æÁ¦, 2. °³¹æÇüº´¿ø
  • peripheral nervous system
    ¸»ÃʽŰæ°è, ¸»ÃʽŰæ°èÅë
  • registration system
    ½Å°íÁ¦µµ, µî·ÏÁ¦µµ
  • reproductive system
    »ý½Ä°èÅë
  • respiratory system
    È£Èí°èÅë
  • reticuloendothelial system
    ±×¹°³»ÇǰèÅë, ¼¼¸Á³»ÇǰèÅë
  • stereotactic system
    Á¤À§°íÁ¤±â
  • urinary system
    ºñ´¢°èÅë
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • macular atrophy
    (¢¡anetoderma) ÇǺÎÀ§ÃàÁõ
  • mast atrophy
    À¯¹æÀ§Ãà
  • muscular atrophy
    ±ÙÀ°À§Ãà
  • myopathic atrophy
    ±ÙÀ°º´ÁõÀ§Ãà
  • neural progressive muscular atrophy
    ½Å°æÁøÇà±ÙÀ°À§Ãà
  • neurogenic muscular atrophy
    ½Å°æÅ¿±ÙÀ°À§Ãà
  • neurospinal muscular atrophy
    ½Å°æÃ´¼ö±ÙÀ°À§Ãà
  • olivopontocerebellar atrophy
    ¿Ã¸®ºê´Ù¸®¼Ò³úÀ§Ãà
  • optic atrophy
    ½Ã°¢½Å°æÀ§Ãà
  • perifollicular macular atrophy
    ÅÐÁýÁÖÀ§¹ÝÁ¡À§Ãà
  • peripapillary chorioretinal atrophy
    À¯µÎÁÖÀ§¸Æ¶ô¸Á¸·À§Ãà
  • pigmentary atrophy
    »ö¼Ò¼ºÀ§Ãà
  • pressure atrophy
    ¾Ð¹ÚÀ§Ãà
  • reticular atrophy
    ¸Á»óÀ§Ãà
  • senile atrophy
    ³ë³âÀ§Ãà
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • gingival atrophy
    Ä¡ÀºÀ§Ãà(öÍó»ê×õê).
  • glaucomatous optic nerve atrophy
    ³ì³»Àå½Ã½Å°æÀ§Ãà.
  • granular atrophy of kidney
    ½ÅÀå°ú¸³¼ºÀ§Ãà.
  • gray optic atrophy
    ȸ»ö½Ã½Å°æÀ§Ãà
  • halisteretic atrophy
    Żȸ¼º À§Ãà(÷­üéàõê×õê).
  • hemilingual atrophy
    ÆíÃø¼³À§Ãà
  • hereditary optic atrophy
    À¯Àü¼º½Ã½Å°æÀ§Ãà.
  • hereditary optic atrophy
    À¯Àü¼º ½Ã½Å°æÀ§Ãà.
  • hypothenar atrophy
    ¼ÒÁö±¸À§Ãà.
  • hypothenar atrophy
    ¼ÒÁö±¸ À§Ãà(á³ò¦Ï¹êÍõê).
  • infantile muscular atrophy =Werdnig-Hoffmann disease
    ¿µ¾ÆÇü±ÙÀ§ÃàÁõ(?ä®û¡ÐÉê×õêñø).
  • infantile muscular atrophy =Werdnig-Hoffmann disease
    ¿µ¾ÆÇü ±ÙÀ§ÃàÁõ(?ä®û¡ÐÉê×õêñø).
  • infantile progressive spinal muscular atrophy
    ¿µ¾ÆÁøÇ༺ ô¼ö¼º ±ÙÀ§Ãà(Áõ).
  • peroneal muscular atrophy
    ºñ°ñ±Ù À§ÃàÁõ(ÝëÍéÐÉê×õêñø).
  • pigmentary atrophy
    »ö¼Ò¼º À§Ãà(ßäáÈàõ ê×õê)
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • central papillary atrophy
    Á᫐ À¯µÎ À§Ãà
  • chorioretinal atrophy
    ¸Æ¶ô¸Á¸·À§Ãà
  • chorioretinal gyrate atrophy
    ³úȸÇü¸Æ¶ô¸Á¸·À§Ãà(¡­éæÍØßÒê×õê).
  • choroidal atrophy
    ¸Æ¶ô¸·À§Ãà
  • cicatricial atrophy
    ÈäÅͼº À§Ãà
  • circulatory optic atrophy
    ÇãÇ÷½Ã½Å°æÀ§Ãà
  • congenital optic atrophy
    ¼±Ãµ½Ã½Å°æÀ§Ãà
  • correlated atrophy
    »ó°üÀ§Ãà(Áõ)(Ë×Ë´Ëô̧̡).
  • cortical atrophy
    ÇÇÁúÀ§Ãà(¡­ê×õê)
  • cyanotic atrophy
    û»ö¼º À§Ãà(ôìßäàõê×õê).
  • cystic atrophy
    ³¶¼ºÀ§Ãà(Ò¥àõê×õê)
  • denervation atrophy
    Å»½Å°æÀ§Ãà(÷­ãêÌèê×õê).
  • denervation muscular atrophy
    Å»½Å°æ¼º ±ÙÀ§Ãà.
  • denervation muscular atrophy
    Å»½Å°æ¼º(÷­ãêÌèàõ) ±ÙÀ§Ãà(ÐÉê×õê).
  • dental atrophy
    Ä¡¾ÆÀ§Ãà(¡­ê×õê).
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • cell-free system
    ¹«¼¼Æ÷(Ùíá¬øà)½Ã½ºÅÛ
  • charge relay system
    ÀüÇÏ(ï³ùÃ) ¸±·¹ÀÌ ½Ã½ºÅÛ
  • charge transfer relay system
    ÀüÇÏÀ̵¿(ï³ùÃì¹ÔÑ) ¸±·¹ÀÌ ¾¾½ºÅÛ
  • closed circuit system
    Æó¼âȸ·Î(øÍáðüÞÖØ) ½Ã½ºÅÛ
  • closed system
    ´ÝÈù ½Ã½ºÅÛ
  • cyclophorase system
    »çÀÌŬ·ÎÆ÷·¹À̽º ½Ã½ºÅÛ
  • digestive system
    ¼ÒÈ­(á¼ûù)½Ã½ºÅÛ
  • DNA replicase system
    DNA ·¹Çø®ÄÉÀ̽º ½Ã½ºÅÛ (ÔÒ) replisome
  • ecological system
    »ýÅÂÇÐÀû(ßæ÷¾ùÊîÜ) ½Ã½ºÅÛ
  • electron transfer system
    ÀüÀÚÀü´Þ(ï³í­îîÓ¹) ½Ã½ºÅÛ
  • electron transport system
    ÀüÀÚ¼ö¼Û(ï³í­âÃáê) ½Ã½ºÅÛ
  • endocrine system
    ³»ºÐºñ¼±(Ò®ÝÂù²àÊ) ½Ã½ºÅÛ
  • endomembrane system
    ³»¸·(Үد) ½Ã½ºÅÛ
  • energy-regenerating system
    ¿¡³ÊÁö Àç»ý(î¢ßæ) ½Ã½ºÅÛ
  • enzyme system
    È¿¼Ò (ý£áÈ) ½Ã½ºÅÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • multiple exostoses
    ´Ù¹ß¼º¿Ü°ñÁõ
  • multiple fibroma
    ´Ù¹ß¼º¼¶À¯Á¾
  • multiple lymphomatous polyposis
    ´Ù¹ß¼º¸²ÇÁÁ¾¼º¿ëÁ¾Áõ
  • multiple myeloma
    ´Ù¹ß¼º°ñ¼öÁ¾
  • multiple overlapping thin slab acquisition [=MOTSA]
    ´ÙÁßÁߺ¹¼¼ÆíÆÇȹµæ
  • multiple polyp
    ´Ù¹ß¼ºÆú¸³
  • multiple sclerosis
    ´Ù¹ß¼º°æÈ­Áõ
  • array system
    ¹è¿­ÀåÄ¡, ¹è¿­Ã¼°è
  • cardiovascular system
    ½ÉÀåÇ÷°ü°è
  • central nervous system [=CNS]
    ÁßÃ߽Űæ°è(Åë)
  • CNS [=central nervous system]
    ÁßÃ߽Űæ°è(Åë)
  • conventional film screen system
    ±âÁ¸Çʸ§Ã¼Áµ
  • digestive system
    ¼ÒÈ­±â°èÅë
  • display system
    Ç¥½ÃÀåÄ¡
  • DOS [=disk operating system]
    µð½ºÅ©¿î¿µÃ¼Á¦
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
MHS major histocompatibility system; malignant hyperthermia in swine; malignant hyperthermia syndrome; m...
MEN Multiple Endocrine Neoplasia
  ; AD Trait
  1. MEN Type I(= Wermer Syndro...
MDS Master of Dental Surgery; maternal deprivation syndrome; medical data screening; medical data system...
MPS meconium plug syndrome; medial premotor system; Member of the Pharmaceutical Society; microbial prof...
MS   1) Mitral Stenosis
  2) Multiple Sclerosis; ´Ù¹ß¼º °æÈ­Áõ
  3) Macro...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
CA Cerebral atrophy
DRPLA Dentato-rubral and pallido-luysian atrophy
DR-PLA Dentato-rubro-pallido-luysian atrophy
GA Geographic atrophy
GA Gyrate atrophy
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • hemilingual atrophy
    ÆíÃø ¼³ À§Ãà
    ÇôÀÇ ÁÂÃøÀ̳ª ¿ìÃøÀÇ ÇÑÂÊ¿¡¼­ À§ÃàÀÌ ÀϾ »óÅÂ.
  • hypoplastic atrophy
    ÀúÇü¼º¼º À§Ãà
  • juvenile progressive muscular atrophy
    ¿¬¼Ò¼º ÁøÇ༺ ±Ù À§ÃàÁõ
  • lacunar optic atrophy
    ÇØ¸é ½Ã½Å°æ À§Ãà
  • late cortical cerebelar atrophy
    ¸¸¹ß¼º ÇǺμº ¼Ò³ú À§ÃàÁõ
  • lichen atrophy
    À§Ã༺ ż±
  • muscle atrophy
    ±Ù À§Ãà
  • muscle disuse atrophy
    Æó¿ë¼º ±Ù À§Ãà
  • optic nerve atrophy
    ½Ã½Å°æ À§Ãà
  • papillary atrophy
    À¯µÎ À§Ãà
  • perifollicular macular atrophy
    ¸ð³¶ ÁÖÀ§ ¹Ý»ó À§Ãà
  • periodontal atrophy
    Ä¡ÁÖ ÅðÃà
  • pontine nuclear atrophy
    ³ú±³ ÇÙÀÇ À§Ãà
  • postinflammatory optic atrophy
    ¿°ÁõÈÄ ½Ã½Å°æ À§Ãà
  • pressure atrophy
    ¾Ð¹Ú À§Ãà
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
multiple ego states Various psychological organizational state's reflecting different personas or life experiences.
(05 Mar 2000)
multiple embolism Embolism caused by the arrest of a number of small emboli.
(05 Mar 2000)
multiple endocrine adenomatosis The presence of functioning tumours in more than one endocrine gland, commonly the pancreatic islets and parathyroid glands, which may be associated with Zollinger-Ellison syndrome; dominant inheritance.
Synonym: multiple endocrine adenomatosis.
(05 Mar 2000)
multiple endocrine deficiency syndrome <syndrome> Acquired deficiency of the function of several endocrine glands, usually on an auto-immune basis.
Synonym: multiple glandular deficiency syndrome.
(05 Mar 2000)
multiple endocrine neoplasia (type I) This is a hereditary disorder in which two or more of the following glands: parathyroid, pancreas, pituitary, adrenals or thyroid develop hyperplasia or a tumour.
(type II) This is a hereditary disorder in which two or more of the following glands: thyroid, adrenal or parathyroid, develop overgrowth (hyperplasia) or malignant cells (cancer). The underlying cause is genetic and a positive family history for this illness is a risk factor.
Incidence: approximately 3 in 100,000 people in the general population.
Origin: Gr. Plassein = to form
(27 Sep 1997)
multiple endocrine neoplasia 1 <radiology> Multiple endrocrine neoplasia syndrome three P's.
Pituitary adenoma, 65% can develop Cushing's, acromegaly, prolactinoma, parathyroid hyperplasia / adenoma, 88% can develop hyper-PTH
pancreatic isleT-cell tumour, gastrinoma (Z-E) most common, 50% of Z-E can develop MEN-1, inconstant features: bronchial/intestinal carcinoid, thyroid adenoma, adrenal cortical tumour, lipoma, thymoma tissue expression
Primary hyperparathyroidism (90%), Gastrinoma (30%), Prolactinoma (15%), Other (10%).
Synonym: Wermer syndrome
(12 Dec 1998)
multiple endocrine neoplasia 2 <radiology> Multiple endocrine neoplasia syndrome, medullary thyroid carcinoma, usually multifocal; metastasis to local nodes, lung, liver, usually calcify in liver, pheochromocytoma, almost always bilateral, parathyroid hyperplasia, may be secondary to calcitonin secreted by medullary thyroid carcinoma inconstant feature: adrenal cortical hyperplasia
Synonym: Sipple syndrome
(12 Dec 1998)
multiple endocrine neoplasia 3 <radiology> Multiple endocrine neoplasia syndrome (type 2B, type 3), medullary thyroid carcinoma, pheochromocytoma, marfanoid habitus (Cf: Marfan syndrome), mucosal neuromas, neurofibromas, ganglioneuromatosis coli More info: MEN syndrome 2B
Synonym: Schimke, marfanoid syndrome
(12 Dec 1998)
multiple endocrine neoplasia type 1 A rare syndrome characterised by hyperplasia and/or neoplasms of the pituitary, parathyroid glands, and pancreatic islets. Hyperparathyroidism occurs in 90% of the cases and is usually the first manifestation of the syndrome. The most frequent pancreatic manifestation is gastrinoma typically leading to zollinger-ellison syndrome. The appearance of this condition has been limited to the loss of allelic heterozygosity at the 11q13 locus on the long arm of chromosome 11. Patients overall exhibit long survival times. Chemotherapy is rare and surgical management is generally dependent on the genetic expression in individual patients.
(12 Dec 1998)
multiple endocrine neoplasia type 2 <syndrome> This is a hereditary disorder in which two or more of the following glands: thyroid, adrenal or parathyroid, develop overgrowth (hyperplasia) or malignant cells (cancer). The underlying cause is genetic and a positive family history for this illness is a risk factor.
Incidence: approximately 3 in 100,000 people in the general population.
(27 Sep 1997)
multiple endocrine neoplasia type 2a A type of multiple endocrine neoplasia characterised by a virtually 100% incidence of medullary thyroid carcinoma, a 50% incidence of pheochromocytoma, and a lesser incidence of parathyroid adenomas associated with hyperparathyroidism. The condition is always transmitted through autosomal dominant inheritance. Genetic testing can identify individuals with the trait in early infancy. Treatment is usually excision of the enlarged parathyroid glands.
(12 Dec 1998)
multiple endocrine neoplasia type 2b A type of multiple endocrine neoplasia occurring as an isolated congenital presentation or as a distinct autosomal dominant disease. It is characterised by the 100% incidence of medullary thyroid carcinoma and frequent pheochromocytomas; patients seldom exhibit hyperparathyroidism. It is distinguished from men 2a by its characteristic physical appearance resulting from numerous neural defects including mucosal neuromas of the eyelids, lips, and tongue. The neural abnormalities also include widespread neurogangliomatosis of the gastrointestinal tract leading to abnormal gut motility. Treatment usually requires total thyroidectomy following evaluation for the presence of pheochromocytomas.
(12 Dec 1998)
multiple epiphysial dysplasia A dominantly inherited abnormality of epiphyses characterised by difficulty in walking, pain and stiffness of joints, stubby fingers, and often dwarfism of short-limb type; on X-ray examination, the epiphyses are mottled and irregular; ossification centres are late in appearance and may be multiple, but the vertebrae are normal. There is also an autosomal recessive form .
Synonym: dysplasia epiphysialis multiplex.
(05 Mar 2000)
multiple exostosis A disturbance of enchondral bone growth in which multiple, generally benign osteochondromas of long bones appear during childhood, commonly with shortening of the radius and fibula; the ill-effects are usually mechanical but malignant change is rare; autosomal dominant inheritance.
Synonym: diaphysial aclasis, hereditary deforming chondrodystrophy, multiple exostosis, osteochondromatosis.
(05 Mar 2000)
multiple fission Division of the nucleus, simultaneously or successively, into a number of daughter nuclei, followed by division of the cell body into an equal number of parts, each containing a nucleus.
(05 Mar 2000)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • Doppler Lidar System
    µµÇ÷¯ È¿°ú¸¦ ÀÌ¿ëÇÑ ±¤ÇÐ½Ä ¼Óµµ°è
  • European Monetary System
    À¯·´ ÅëÈ­ Á¦µµ
  • Federal Reserve System
    ¿¬¹æÁغñÁ¦µµ
  • Gary system
    °Ô¸®½Ä Çб³ Á¦µµ
  • Harvard system
    ÇϹöµå ½Ã½ºÅÛ(Çмú¼­,ÀâÁöÀÇ Âü°í ¹®Çå Ç¥½Ã¹ýÀÇ Çϳª)
  • Information Network System
    °íµµ Á¤º¸ Åë½Å ½Ã½ºÅÛ
  • Montessori method(system)
    (ÀÌÅ»¸®¾ÆÀÇ ¿©¼º ±³À°°¡ À̸§¿¡¼­) ¸óÅ×¼Ò¸®½Ä ±³À°¹ý(¾Æµ¿ÀÇ ÀÚÁÖ¼ºÀÇ ½ÅÀåÀ» Áß½ÃÇÑ ±³À°¹ý) m`
  • PA system
    =PUBLICADDRESS SYSTEM
  • Ptolemaic system
    õµ¿¼³
  • ascent propulsion system
    ¿ìÁÖ Á¤°ÅÀå ±Íȯ¿ë ·ÎÄÏ ¿£Áø
  • barter system
    ¹ÙÅÍÁ¦
  • call connect system
    ÀüÈ­ Á¢¼Ó±â(¿Ü¼±.³»¼± ÀüÈ­¿ÍÀÇ)
  • case system
    ÆÇ·Ê Áß½ÉÀÇ ±³À°¹ý 1
  • centerofmass system
    Á߽ɰè(°èÀÇ Áß½ÉÀÇ ¿îµ¿·®ÀÌ ¿µÀÌ µÇµµ·Ï ÃëÇÑ ÁÂÇ¥°è)
  • central alarm system
    Áß¾Ó °æº¸ ÀåÄ¡(ÀÚµ¿ÀûÀ¸·Î °æÂû.°æºñ ȸ»ç µî¿¡ Å뺸µÇ´Â)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
ÅëÇÕ°Ë»ö ¿Ï·á